Novo Nordisk’s (NVO) CagriSema Phase 3 trial results have been described as “underwhelming” by UBS analyst Trung Huynh. The data showed an average weight loss of 20.4%, which falls short of the company’s prior guidance of 25%. This result is also lower than Eli Lilly’s (LLY) tirzepatide at a similar timepoint.
However, UBS sees CagriSema as a positive read-through for Lilly and Amgen (AMGN). The analyst believes that the data validates tirzepatide’s best-in-class profile. For Novo, the results suggest that CagriSema may be less attractive compared to MariTide due to potential gastrointestinal intolerability issues.
In comparison, MariTide is a monthly titration regimen, which may give it an edge over CagriSema. The analyst’s comments provide insight into how investors should view Novo Nordisk’s obesity treatment prospects and their connections to other companies in the space.
Source: https://finance.yahoo.com/news/novo-obesity-data-positive-eli-123043312.html